149 related articles for article (PubMed ID: 102417)
21. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
22. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
Moore DH; Fowler WC; Jones CP; Crumpler LS
Am J Obstet Gynecol; 1991 Sep; 165(3):573-6. PubMed ID: 1909840
[TBL] [Abstract][Full Text] [Related]
23. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
25. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
26. Hexamethylmelamine and pentamethylmelamine: an update.
Hahn DA
Drug Intell Clin Pharm; 1983 Jun; 17(6):418-24. PubMed ID: 6407810
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
28. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
29. cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Krauss S; Tornyos K; DeSimone P; Lowenbraun S; McKeown J; Solomon A; Sonoda T
Cancer Treat Rep; 1979 Mar; 63(3):391-3. PubMed ID: 106964
[TBL] [Abstract][Full Text] [Related]
30. Hexamethylmelamine treatment of sarcomas and lymphomas.
Borden EC; Larson P; Ansfield FJ; Bryan GT; Johnson RO; Ramirez G; Wilson WL
Med Pediatr Oncol; 1977; 3(4):401-6. PubMed ID: 412045
[No Abstract] [Full Text] [Related]
31. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
[TBL] [Abstract][Full Text] [Related]
32. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy with CCNU (NSC-79037),hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in advanced bronchogenic carcinoma.
DiBella NJ; Nelson RA; Norgard MJ
Oncology; 1975; 32(2):82-5. PubMed ID: 815858
[TBL] [Abstract][Full Text] [Related]
34. cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancer.
Lopez JA; Krikorian JG; Dias SF; Spiers AS; Finkel HE; Barnard DE
Gynecol Oncol; 1981 Feb; 11(1):64-7. PubMed ID: 6781990
[No Abstract] [Full Text] [Related]
35. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
Hauge MD; Long HJ; Hartmann LC; Edmonson JH; Webb MJ; Su J
Invest New Drugs; 1992 Nov; 10(4):299-301. PubMed ID: 1487403
[TBL] [Abstract][Full Text] [Related]
37. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
38. [Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].
Pinon G; Pinel MC; Goudier MJ; Coiffier B; Filippi MH; Goupil A; Roullet B; Facchini T; Mignot L; Tresca P
Bull Cancer; 1991; 78(12):1119-31. PubMed ID: 1786425
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
40. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer.
Wharton JT
Cancer Treat Rev; 1991 Mar; 18 Suppl A():15-21. PubMed ID: 1904304
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
